HC Wainwright Reiterates Buy Rating for Celldex Therapeutics
Celldex Therapeutics maintains a buy rating with a $42 target from HC Wainwright.
Key Points
- HC Wainwright reiterated its buy rating for Celldex Therapeutics, setting a price target of $42 on June 15, 2026.
- Celldex Therapeutics, trading at $31.27, has a market cap of approximately $2.45 billion and a 52-week high of $35.79.
- Insiders and analysts show strong interest, with recent insider buys and multiple buy ratings from firms like UBS and Wells Fargo.
HC Wainwright reiterated its buy rating for Celldex Therapeutics, Inc. (NasdaqCM: CLDX) on June 15, 2026, setting a price target of $42. Shares of Celldex traded at $31.27 on the same day, reflecting continued confidence from analysts in the company's prospects.
Other Institutional Activity in Celldex Therapeutics
Wellington Management Group LLP increased its holdings by 480,868 shares, bringing its total to 8,560,476 shares valued at about $271.5 million. Meanwhile, Kynam Capital Management, LP trimmed its position by 102,613 shares, leaving it with 5,840,567 shares worth $185.3 million. BlackRock, Inc. also reduced its stake by 81,930 shares, resulting in 5,369,885 shares valued at $170.3 million. FMR LLC made a significant reduction of 1,158,421 shares, ending with 3,749,048 shares valued at about $118.9 million. Point72 Asset Management, L.P. boosted its position by 1,471,582 shares, now holding 3,229,939 shares worth approximately $102.5 million.
Celldex Therapeutics Stock Snapshot
Shares of Celldex Therapeutics are trading near $31.27, with a market capitalization of approximately $2.45 billion. The company's stock has a 52-week low of $19.52 and a high of $35.79. It has a 50-day moving average of $31.95 and a 200-day moving average of $27.80. Celldex's current ratio stands at 8.92, with a quick ratio of 8.78 and a debt-to-equity ratio of 0.42.
Recent Earnings
Celldex reported revenue of $865,000, with a revenue growth rate of -97.8%. The company has not been profitable, posting an EPS of -$4.27 and a return on equity of -48.94%. Celldex's net margin is currently at 0.0%. The next earnings report is expected on August 6, 2026.
Insider Buying and Selling at Celldex Therapeutics, Inc.
Martin Samuel Bates, Senior Vice President and CFO, executed multiple transactions on January 2, 2026, buying 4,817 shares at $10.38 per share and selling the same amount. Ronald Pepin, Senior Vice President and Chief Business Officer, bought 19,333 shares at $5.47 per share on December 15, 2025.
Analysts Set New Price Targets
On June 15, 2026, HC Wainwright & Co. reiterated its buy rating for Celldex with a $42 price target. UBS maintained its buy rating with a $45 target on June 10, 2026. Wells Fargo also maintained a buy rating with a $54 target as of May 13, 2026. Barclays upgraded its rating to buy with a $45 target on April 20, 2026.
About Celldex Therapeutics
Celldex Therapeutics, Inc. is a biopharmaceutical company based in Hampton, New Jersey. It focuses on developing therapeutic antibodies for severe inflammatory, allergic, and autoimmune diseases. The company's pipeline includes monoclonal and bispecific antibodies targeting mast cell-mediated diseases. Key programs include Barzolvolimab, a monoclonal antibody that inhibits the KIT receptor, and CDX-622, a bispecific candidate for inflammatory diseases. Celldex is led by CEO Anthony S. Marucci and employs about 198 people.
Bottom Line
Celldex Therapeutics continues to attract attention from analysts and investors, with HC Wainwright reiterating its buy rating and setting a $42 price target. The company's stock performance and strategic initiatives in biotechnology make it a subject of interest. As always, it's important to remember that analyst ratings are based on past data and may not reflect future performance.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.